Research study for adults with Multiple Sclerosis


16467

A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis

Neurology

Goldman Myla, D

UVa Health System, Department of Neurology, seeks adults, ages 18 to 65 with relapsing-remitting multiple sclerosis for research study. The purpose of the study is to see if a medication called Gilenya® (at the approved dose or an investigational lower dose) is superior to Copaxone® in reducing the relapse rate in people with MS. The study involves taking one of 2 doses of Gilenya® by mouth, or Copaxone® by injection daily for up to 12 months. The study also requires blood draws, brain MRI’s, surveys, neurological assessments and testing. There are 8 visits over about 15 months, each visit lasting from 45 minutes to 8 hours. ? Study-related exams, tests and experimental medication provided free of charge. ? Compensation for study completion is $50 for each completed study visit For more information please contact: • Margaret Keller RN • 434-243-5457 or mfk8e@virginia.edu • IRB-HSR # 16467 Principal Investigator: Myla Goldman MD


Adult

Multiple Sclerosis

Neurology

Ill

No Compensation

Margaret Keller

mfk8e@virginia.edu

4342435457